Abstract: A mold structure includes gate electrodes stacked on a first substrate, a channel structure penetrating a first region of the mold structure to cross the gate electrodes, a first through structure penetrating a second region of the mold structure, and a second through structure penetrating a third region of the mold structure. The mold structure includes memory cell blocks extending in a first direction and spaced apart in a second direction, and a dummy block extending in the first direction and disposed between the memory cell blocks. Each of the memory cell and dummy blocks includes a cell region and an extension region arranged in the first direction. The first region is the cell region of one of the memory cell blocks, the second region is the extension region of the one of the memory cell blocks, and the third region is the extension region of the dummy block.

Abstract: In some implementations, is provided a battery cell, and battery module and battery pack including the same including: an electrode assembly in which a plurality of polar plates are stacked; a case having an internal space in which the electrode assembly is accommodated; a cap assembly coupled to the case and having a terminal disposed therein; and a connection pin configured to electrically connect the electrode assembly and the terminal, wherein the terminal includes: a rivet having an insertion hole into which the connection pin is inserted; and a terminal portion coupled to the rivet.

Abstract: A semiconductor memory device includes a mold structure including gate electrodes stacked on a first substrate, a channel structure that penetrates a first region of the mold structure to cross the gate electrodes, a first through structure that penetrates a second region of the mold structure, and a second through structure that penetrates a third region of the mold structure. The mold structure further includes memory cell blocks extending in a first direction and spaced apart in a second direction, and a dummy block extending in the first direction and disposed between the memory cell blocks. Each of the memory cell blocks and the dummy block includes a cell region and an extension region arranged in the first direction. The first region is the cell region of one of the memory cell blocks, the second region is the extension region of the one of the memory cell blocks, and the third region is the extension region of the dummy block.

Abstract: According to a method of transforming a message passing interface (MPI) program, an MPI function is parsed such that a computer may directly access data created by another computer through a memory when an MPI parallel program is executed on a computer system for distributed processing, a network function corresponding to the MPI function is created for network communication, and a bus line function is created for directly accessing the memory through a bus line.

Abstract: A composition for prevention or treatment of metabolic syndrome or for antioxidation includes black soybean leaf extracts and flavonol glycoside compounds isolated thereof as active ingredients.

Abstract: According to a method of transforming a message passing interface (MPI) program, an MPI function is parsed such that a computer may directly access data created by another computer through a memory when an MPI parallel program is executed on a computer system for distributed processing, a network function corresponding to the MPI function is created for network communication, and a bus line function is created for directly accessing the memory through a bus line.

Abstract: The present invention relates to a composition for prevention or treatment of metabolic syndrome or for antioxidation comprising black soybean leaf extracts and flavonol glycoside compounds isolated thereof as active ingredients.

Abstract: A nonvolatile memory device may include a first well area formed on a substrate, a plurality of channel layers disposed on the first well area and extended in a first direction substantially perpendicular to a surface of the first well area on which the channel layers are disposed, and a plurality of gate conductive layers stacked on the first well area along side walls of the plurality of channel layers, the plurality of gate conductive layers having a first edge area and a second edge area, wherein a first part of the first edge area is disposed outside of the first well area.

Abstract: The present invention relates to a mannanase produced from Celluosimicrobium sp. strain HY-13 and more particularly to a highly active novel mannanase produced from Cellulosimicrobium sp. strain HY-13 as separated from an invertebrate. The mannanase produced from the said Cellulosimicrobium sp. strain HY-13 can be used in the decomposition of a mannan found in hemicellulose contained in grains and plants and in enhancing the utility value of a hydrolysate, which uses the decomposed mannan, for the transformation of biomass or as an animal feed material.

Abstract: The present invention relates to a mannanase produced from Celluosimicrobium sp. strain HY-13 and more particularly to a highly active novel mannanase produced from Cellulosimicrobium sp. strain HY-13 as separated from an invertebrate. The mannanase produced from the said Cellulosimicrobium ap. strain HY-13 can be used in the decomposition of a mannan found in hemicellulose contained in grains and plants and in enhancing the utility value of a hydrolysate, which uses the decomposed mannan, for the transformation of biomass or as an animal feed material.

Abstract: The invention provides a method for treating lung cancer or breast cancer wherein the method comprises administering a pharmaceutically effective dose of arazyme enzyme to a subject with lung cancer or breast cancer. The arazyme enzyme is either a protein comprising the amino acid sequence of SEQ ID NO: 1; and/or a protein encoded by DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 2.

Abstract: The present invention relates to a composition and a method for the treatment of liver dysfunction which contains administration of a composition containing arazyme as an active ingredient, more precisely arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects the liver by inhibiting liver injury around the central vein region. Therefore, the arazyme of the invention can be effectively used as a composition for the treatment of liver dysfunction.

Abstract: There are provided a novel xylanase and a use of the same. In detail, there are provided a xylanase separated from a Cellulosimicrobium funkei HY-13 strain, a Fibronectin Type 3 domain of the xylanase, and a use thereof. Since determining that the xylanase having substrate specificity degrades xylan at neutral and basic pH with high efficiency and the Fn3 domain does an important role with respect to the substrate specificity, the xylanase according to the present invention may be added to various vegetable feed materials or be efficiently used to improve degradation ability of cellulosic biomass.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for treating liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

Abstract: The present invention relates to a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme as an active ingredient, more precisely a pharmaceutical composition for the prevention of liver dysfunction which contains arazyme produced by Aranicola proteolyticus. The arazyme of the present invention inhibits apoptosis in injured liver cells, increases SMP30 expression, inhibits P-smad3 expression and protects liver by inhibiting liver injury around central vein region. Therefore, the arazyme of the invention can be effectively used as a pharmaceutical composition for the prevention of liver dysfunction.

Abstract: Disclosed herein is a composition containing arazyme as an active ingredient for prevention and treatment of arthritis. More specifically, arazyme produced from Aranicola proteolyticus of the present invention may be useful as a composition for prevention and treatment of arthritis by inhibiting the expression of TNF-? which is an inflammation-inducing factor and preventing the loss of proteoglycan and collagen from joint cartilage to inhibit the progression of arthritis and protect joints.

Abstract: The present invention relates to a pharmaceutical composition for the prevention and treatment of cancer comprising arazyme as an active ingredient. More precisely, when arazyme produced by Aranicola proteolycius was administered to the nude mice transplanted with human lung carcinoma cell line, weight gaining, inhibition of tumor cell growth and infiltration, and down-regulations of MMP-9, NF-?B and PCNA, were observed. In addition, when arazyme was treated to human breast cancer cells (MDA-MB-231), down regulations of p21, PCNA (Proliferating Cell Nuclear Antigen), VEGF (Vascular Endothelial Growth Factor), BCl2 (B-cell CLL/lymphoma 2), p-p38, PKC (Protein Kinase C) and MMP-1 (Matrix MetalloProteinase-1) which are involved in tumor cell growth, differentiation, proliferation and metastasis, were observed along with the up-regulation of catalase which inhibits tumor development. Therefore, the arazyme can be effectively used as a pharmaceutical composition for the prevention and treatment of cancer.

Abstract: The present invention relates to a protease, and more specifically to a protease derived from Aranicola proteolyticus, a gene coding for said enzyme, a gene expression system for said protease, a process for purifying the protease, and the uses of said protease in industrial applications, such as for example, detergents, cosmetics, leather processing agents, chemicals for laboratory research, solubilizing or softening agents for food, meat modifier, feed or food additives, or oil and fat separating agents, as well as pharmaceutical compositions.

Abstract: The present invention relates to a paecilomyces genus microorganism and microbial insecticide for controlling the soil pests using the same, more particularly to a paecilomyces genus microorganism having insecticidal activity to soil pests and a microbial insecticide for controlling the soil pests containing the same. Since the microbial insecticide of the present invention shows excellent insecticidal activity to harmful soil pests, it can effectively be used as a environment-compatible insecticide to prevent the soil pests from farmland crops.